Substitute for Form 1449 A. & EPTO  INFORMATION DISCLOSURE  STATEMENT BY APPLICANT  (use as many sheets as necessary)							Complete if Known					
							policati	on Number	Unknown			
							nfirma	tion Number	Unknown			
									April 25, 2006			
										-		
	T <sub>1</sub>	- 1	Tof I i									
cci	1,		OI .			LA	ionicy	DOCKET NUMBER	Q94201			
				U.S. P	ATENT	DOCI	MEN	TS				
Document Number						DOC	1					
Cite			Kind I						or Applicant of Cited Document			
No."	Number		(If known) M		MM-DU-YYYY		1					
	US		-	$\neg$								
	US											
	US											
	US											
	US											
Cite No.1				Kind C	Code MM-					Translation <sup>4</sup>		
Cita	I Toulode name								The law Dook warning			
No.1	journal, secial, symposium, catalog, etc.), date, page(s), volume issue nember(s), publisher, city, and/or country where published.											
	J. PAN et al., "Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells											
	Journal of Virology, Vol. 75, No. 1, 2001, pp. 215-225									_		
	A. ARLT et al., "Inhabition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis											
	induced by etoposide (VP16) or decorabicin", Oncogene, Vol. 20, No. 7, Feb. 2001, pp. 859-868  N. KATO et al., "Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most											
	N. K.A.1.O et al., "Activation of intracellular signating by hepatitis B and C viruses: C-viral core is the most potent signal inducer", Hepatology, Vol. 32, No. 2, 2000, pp. 405-412											
	notant cional			S MUERKOSTER et al., "Usage of NF-kappa B mhibitor sufasalazine as sensitizing agent in combined								
	potent signal	inducer", H	epaton	ogy, vo	C Lorenz D	a hibit			timed	_		
	potent signal S_MUERKO	STER et al.,	"Usa	ge of N	F-kappa E	mhibet	or sufas	alazine as sensitizin o. 4, Apr. 2003, pp.				
	Clie No.1	STATEMENT	STATEMENT BY APP	STATEMENT BY APPLICA	STATEMENT BY APPLICANT   (size as many sheets as necessary)	STATEMENT BY APPLICANT	STATEMENT BY APPLICATI   FR	Confirm DISCLOSURE   ConfirM	Confirmation Number	INFORMATION DISCLOSURE   STATEMENT BY APPLICANT		

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPP 660. Door line through citation if not in conformance and not

Implicate; usings claims designates market (options). Then Kind Codes of ENTO Point Documents of www.napin.gov. MRTF 995.04 or in the contract box of this decrease. If we have been code (WINTO Sental Documents of were code (WINTO Sental Documents) and the code (WINTO Sental Documents). The National Sental Sen

considered Include copy of this form with next communication to ambient